‘Accellerating is difficult for startups in the Netherlands’
17-11-2026 | Interviewer: Juul Vaandrager | Author: Jan Bletz | Image: Jos Derckx
Europe has no shortage of scientific talent. European researchers are frequently cited, and Delft is considered as one of the world’s largest quantum hubs. Yet few international market leaders emerge from that knowledge base. Start-ups get bogged down early on due to university procedures. And when they want to scale up, European capital proves scarce.
What does it take for innovative companies to grow into European champions? Juul Vaandrager, deputy director of the Dutch Private Equity and Venture Capital Association (NVP), posed that question to two individuals who are familiar with this challenge from different perspectives. Anne-Marije Zwerver is CEO and co-founder of Groove Quantum – a spin-off of QuTech that develops quantum computers based on the semiconductor germanium. Felice Verduyn-van Weegen is a partner at the investment firm EQT Life Sciences and invests in biotech companies. EQT also manages the Scaleup Europe Fund, which aims to invest five billion euros in European technology companies from the Series B funding stage onwards.
You are both working on innovation, though in different roles. Who are you, and what drives you?
Zwerver: ‘I studied Systems Engineering, Policy Analysis and Management in Delft, but I missed the technical depth of engineering. So, I also took up physics, where I became fascinated by quantum mechanics. I earned my PhD on semiconductor-based quantum computers. Together with Intel we demonstrated, among other things, that they can be produced in the same way the industry currently manufactures chips. It then turned out that germanium is ideally suited for the fabrication of quantum bits (qubits). In late 2022, my co-founder and I won an EIC Transition Grant; in 2023, we quit our jobs, and in 2024, Groove Quantum was founded. We now have a quantum computer running on a processor with 18-qubits; that is a record in our sector. We achieved this with an EIC grant and a small NWO grant, while others raised hundreds of millions. We have since secured a seed round and grants totaling sixteen million euros.
What drives me is curiosity. I find it fascinating that we do not actually understand quantum mechanics but can still use it for calculations. My entire family started their own businesses but I always thought that was not for me. Then I became an entrepreneur because I believe in this technology. And the potential is immense: in McKinsey’s latest annual quantum report, Delft ranked among the top four largest quantum hubs in the world. It will be interesting to see if we can hold onto that position, as the whole world is now investing heavily in quantum.’
Verduyn-van Weegen: ‘I studied biological psychology and neuroscience and intended to pursue a PhD. But while working in a lab in Boston, I heard stories from people in the business world. That led me to McKinsey; after that, I completed an MBA at Columbia. In 2015, everything came together for me at LSP, an established life sciences venture capital firm that was subsequently acquired by EQT four years ago. I am a partner there, focusing primarily on investments in biotech companies across all stages of development. Recently, I also joined the life sciences investment committee of the Scaleup Europe Fund. We evaluate about 2,000 investment opportunities per year in biotech and medtech, more than sixty percent of which are from Europe.
It may sound cliché, but I look for work that challenges me intellectually, involves a fast pace, and allows me to have an impact, such as now on promoting patient health. Another thing I find excellent is that there is suddenly a focus on the entire ecosystem to see how the Netherlands and Europe can become more innovative. That gives me a great deal of energy.’
The Netherlands excels in science. Why are we less successful at building international market leaders?
Verduyn-van Weegen: ‘We certainly do not lack talented scientists; European researchers are cited incredibly frequently. But making the leap to a company is difficult. This is partly due to the mindset: collaboration with industry is often viewed with skepticism, there is a reluctance to patent too early, and career advancement is almost entirely driven by academic publications. In addition, much of the funding has shifted to later-stage investments. Investors who need to generate returns within a ten-year fund cycle prefer to enter at a later stage. And in the very final phase, many biotech companies need a large foreign partner. A Phase 3 clinical trial requires a vast number of patients; some companies need to raise billions. There was no instrument for that in Europe. So they turn to American investors, and that is when we often lose them. Even entrepreneurs who reinvest after a sale often do so elsewhere. That is why we fail to build any real momentum, although Europe certainly offers plenty of opportunities, too.’
What is the biggest challenge in turning a technological breakthrough into a company?
Zwerver: ‘I agree with Felice. Take QuTech, for example: the Delft-based quantum institute that has spawned many companies. It was founded in 2014, but the initial focus was purely on groundbreaking scientific research. It was not until around 2018 that an active patent strategy emerged. It was only once there were two or three quantum companies that many more followed. Without role models, such an ecosystem gets left behind. One thing that did work well was that QuTech itself, through an NWO grant, was able to award targeted grants of up to €500,000 to startup initiatives – a focused and flexible way to kickstart new companies.
The second challenge is bureaucracy. What we encountered (and still encounter) as a startup in the early years is bizarre. For example, our EIC grant was awarded to the university from which we were spun off. As a result, all the equipment and the intellectual property (IP) legally ended up with the university. We then had to buy back our own IP and equipment. In addition, the commercialization negotiations moved slowly. And as long as that agreement was not in place, we could not attract investors.’
What is different in the United States?
Verduyn-van Weegen: ‘Over there, you are handed everything on a silver platter. There is funding, a network of entrepreneurs, experts, and advisors, and access to seed capital. Every professor there is an entrepreneur, and the level of ambition in every startup is incredibly high.’
Zwerver: ‘And there are standard contracts: the university takes ten or twelve percent of the shares, instead of the twenty-five percent that is customary here. Dutch universities are now also working on introducing such standard contracts. That is a step in the right direction – provided those contracts end up favoring entrepreneurs a bit more.’
The Wennink Report estimated at the end of 2025 that the Netherlands would need to invest an additional 151 to 187 billion euros by 2035 to grow the economy. This capital should primarily be invested in a few strategic sectors, such as quantum technology, biotech, and the semiconductor industry. Is that justified?
Verduyn-van Weegen: ‘I think it is good that there is momentum now, and we need to maintain it. The choice of sectors Wennink identifies makes sense: Europe is already strong in these areas. It makes no sense to try to become a leader in sectors where we do not yet have a solid foundation. That ship has sailed.
For biotech, late-stage financing is crucial. At that stage, companies often Americanize because there is not enough capital in Europe. You then end up competing with American mutual funds, which typically require you to hire an American team, open an office in the U.S., and be available during U.S. business hours. EQT Life Sciences has extensive expertise in taking companies public on U.S. exchanges or selling them to U.S. buyers. But sometimes we would prefer to take a company one step further, so that it can make its own decisions as a European company. However, there is five times less capital available in Europe, especially for late-stage investments. There is also no European stock exchange yet with sufficient depth and liquidity for innovative companies. That was also the reason for establishing the Scaleup Europe Fund – to offer a serious European alternative.’
Anne-Marije, you recently raised funds. Are European investors willing to take enough risk?
Zwerver: ‘We succeeded with a funding round that is entirely European and with a fantastic syndicate! But while raising the round, I did notice the rigidity of the European ecosystem. Quantum computers are an expensive hobby: by the time we have purchased all our equipment, we will have spent 4 to 5 million euros – and will not even have started working yet. So a larger seed round made sense. Seed investors, however, thought ten million was far too much. And the funds that could actually commit that amount found it too risky to get involved at such an early stage. We fell into a sort of gap. American investors, by contrast, showed no such hesitation. Companies that are further along than we are advise: ‘Make sure you have American investors in your next round, otherwise will hit a wall.’ I would love to stay in Europe, but there are only a handful of large funds here that might be interested. The options are limited.’
Can European pension funds help bridge that gap?
Verduyn-van Weegen: ‘There is certainly an opportunity there. In the U.S., a significant portion of pension funds has long been directed toward venture capital. For European funds, it is sometimes even easier to raise money in the U.S. than in Europe. Here it happens only on a small scale, out of a strong sense of responsibility – after all, it is all of our pensions at stake. Yet European venture capital is performing well – according to recent figures, even outperforming its American counterpart. Yes, it carries more risk, so you have to think carefully about where you invest your pension funds. But the question is not whether you should do it, but how.’
And what about the exit climate?
Verduyn-van Weegen: ‘An initial public offering (IPO) in Europe remains challenging because the market lacks the depth required for innovative companies. Anyone who wants to list on a U.S. exchange has to bring an American partner on board, and then the company becomes increasingly Americanized. Acquisitions by pharmaceutical firms are a good route: two-thirds of the new drugs in the pipeline in the pharmaceutical sector come from biotech. But many buyers are American. If we become too dependent on the U.S., that could backfire on us.’
Zwerver: ‘In the biotech sector, early exits were mainly acquisitions, but IPOs are now also happening. The Finnish company IQM deliberately listed on both the Nasdaq and the Helsinki Stock Exchange in July to remain in Europe. Although an exit is obviously still a long way off for us, we share that long-term vision: going public independently, as an anchor in Europe. An acquisition always remains an option, but realistically speaking, at this point you would likely end up with American buyers.’
Verduyn-van Weegen: ‘Let me add something positive: we are seeing more and more European champions emerging. Merus, based in Utrecht, was acquired by Genmab last year for $8 billion. Other examples include Argenx and New Amsterdam. Funds are getting bigger, there are more experienced entrepreneurs, and there is momentum. There is room for improvement, but the opportunities are greater than ever.’
The government is establishing a National Investment Institution (NII). What problem should the NII primarily address?
Zwerver: ‘We are good at launching startups and bringing them to a certain point. After that, scaling up is difficult, and you quickly end up bringing in American or Asian investors. The NII should fill this gap: helping companies that have raised a Series A round to also raise Series B and C rounds.
Quantum is a clear example. In 2021, 615 million euros from the National Growth Fund was allocated to quantum technology. With that, we built hubs in Delft, Amsterdam, Leiden, Eindhoven, and Twente, generated a significant amount of IP, and launched startups. The whole world was watching us. Since then, the countries around us have poured billions into quantum technology. And now the Netherlands is saying: ‘From here on out, the market will take over.’ But if our foreign competitors are heavily backed by their governments while we are not, we are bound to fall behind.’
If you start something, you have to see it through?
Zwerver: ‘Exactly. And the government should more often act as the first customer. Give us a clear mandate, for example: build a quantum computer with 500 qubits. No one has ever done that before. If you end up with 200, you have not formally met the goal, but technologically, you have achieved a world-class feat.
What does not work is spray and pray. An example: twenty-five million euros in government funding for a quantum project with twenty-eight consortium partners. Everyone gets between 300,000 and 700,000 euros, an amount that is not enough for anyone to make a real impact. Instead, focus on a handful of parties who can build something substantial with and, in turn, stimulate the (quantum) market. Otherwise, you end up with only early-stage startups, and the Netherlands will remain the training ground for the rest of the world.’
Verduyn-van Weegen: ‘Sectors like ours require highly specialized knowledge. If you are going to invest heavily in certain projects, do so with the right expertise and involve the funds that have been building that knowledge for years. In biotech, the number of startups could also increase to strengthen the entire value chain. We are also talking about highly international sectors here. So, we should also look at how we can become stronger by collaborating, both within and outside Europe.’
How should the NII and the Scaleup Europe Fund relate to one another?
Verduyn-van Weegen: ‘We share the same mission and agree on the focus areas. Let us make sure we reinforce each other and avoid duplicating efforts, and work together with existing institutional investors.’
Expertise sometimes resides in countries we may not want to be overly dependent on. How do you view the tension between collaboration and strategic autonomy?
Verduyn-van Weegen: ‘I would focus on the question of how we make Europe stronger. If we participate on the world stage as an equal partner, we will also maintain access to the innovations emerging elsewhere. If we stop participating, we will be left behind.’
Zwerver: ‘In our field, we collaborate internationally extensively – in academia and even as companies. That helps everyone move forward faster. But lately, Europe has perhaps been relying too readily on the idea that if something is developed in Asia or America, we can simply buy it from there. Geopolitically and economically, that is a vulnerable strategy. Europe must strive to remain sovereign in key technologies, while simultaneously strengthening one another through international cooperation.’
What needs to have changed ten years from now for us to be able to say that the Netherlands has truly harnessed its innovative potential?
Zwerver: ‘First and foremost, less bureaucracy: a supportive environment for startups, faster decision-making, and less paperwork – without sacrificing important regulations. And second: beyond a strong launchpad for startups, a clear path to growth for scale-ups in later stages.’
Verduyn-van Weegen: ‘More funding would be great, but we also need the corresponding ambition. You can only compete at the highest level if you have that ambition. And we must not let the current momentum fade. If we can sustain that, I am confident that, ten years from now, Europe will be growing thanks to profitable innovations.’
This interview was published in Management Scope 10 2026.
This article was last changed on 17-11-2026